Reshma Kewalramani, CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 17,135 shares at $407.00 ($7.0M) on 2023-12-15, disclosed to the SEC on 2023-12-19.
Scheduled sale ($7.0M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| VRTX | SELL | 2024-11-12 | $7.8M | — | Filing → |
| VRTX | SELL | 2024-08-01 | $7.7M | — | Filing → |
| VRTX | SELL | 2024-07-24 | $7.6M | — | Filing → |